A variety of recombinant proteins derived from protein pVI of human adenovirus type 2 (Ad2) were analysed for their ability to bind Ad2 hexon in vitro. As pVI is also required for activation of the adenovirus-coded protease, the same pVI derivatives were assessed for their ability to activate recombinant adenovirus-coded 23K protease. Two regions, between amino acid residues 48-74 and 233-239 of pVI, were required for the interaction with hexon. These regions are highly conserved amongst mastadenovirus pVI proteins. Both these regions are capable on their own of binding hexon weakly but must be provided in cis for strong hexon binding. In addition, we found evidence to indicate that conformation as well as sequence was important for good hexon binding in our assays. Authentic processing of the appropriate recombinant pVI derivatives, by the recombinant protease, was obtained without the addition of other cofactors. These findings are discussed in relation to the role of pVI in triggering the adenovirus maturation pathway.
Introduction
Adenovirus (Ad) virions are non-enveloped and icosahedral in structure, containing a double-stranded DNA genome of approximately 36000 bp (Akusjarvi et al., 1984) . Mature adenovirus particles can be divided broadly into two parts: core and capsid. The core contains viral DNA covalently bound to terminal protein (TP) together with at least three other proteins: namely V, VII and mu. The major structural component of the capsid is the hexon (a homotrimer of hexon polypeptides) which forms the 20 facets of the icosahedron with penton base and fibre proteins forming the vertices. Hexons can be subdivided into groups of nine (GONs) and peripentonal hexons-the GONs form the facets and the peripentonal hexons are the link between the facets and the pentons. Proteins IIIa, VI, VIII and IX are also associated with the capsid proteins and are thought to be 'cement' proteins. Stewart et al. (1993) used X-ray crystallography, electron microscopy and difference imaging to determine the locations of the capsidassociated polypeptides based on electron density and the stoichiometry of the structural polypeptides.
A number of these structural proteins (IIIa, VI, VII, VIII, TP, mu) are made as precursors, undergoing proteolysis late in the replication cycle by a virus-coded * Author for correspondence. Fax +44 1334 463400. e-mail wcr @ st-andrews.ac.uk protease located within the adenovirus particle (Anderson et al., 1973) . The protease is activated by interaction with a peptide derived from the C-terminal 11 amino acids of the precursor to protein VI, pVI (Mangel et al., 1993 ; Webster et al., 1993) . A temperature sensitive mutant of adenovirus type 2 (Ad2 tsl) is defective in protease function at the restrictive temperature (Weber, 1976) . This mutant produces apparently complete virus particles that are not infectious and fail to proceed beyond the primary endosomal stage of entry into a host cell (cf. Russell & Kemp, 1995) .
Recently we have published work describing an in vitro method (termed west-western blotting) of studying the interactions between two of the structural proteins, namely, VI and hexon (Matthews & Russell, 1994) . We demonstrated that proteolytic processing of pVI to VI proceeds in two stages via an intermediate 0VI) and each cleavage event improved the binding of hexons to the protein in our in vitro assays. Furthermore, we proposed that hydrophobic interactions are critical and that the determinants of the interaction are conserved amongst mastadenoviruses. As a consequence of its predicted location in the capsid (underneath the peripentonal hexons) we suggested that the cleavage of pVI and its association with the hexons may play a role in both final capping of the assembled virus and dismantling of the virus post-infection. Thus protein VI and its precursor appear to be pivotal to the maturation of the adenovirus. In this paper, we describe the expression of a range of recombinant proteins derived from pVI of the prototype strain Ad2. These recombinant proteins were investigated both for their hexon binding properties and their ability to activate adenovirus protease in vitro.
Methods
Western and west-western blotting. Procedures and materials were as described in Matthews & Russell (1994) . Briefly, for west-western blotting one protein is immobilized on nitrocellulose-either spotted directly onto the support or transferred to the nitrocellulose after SDS-PAGE. The second protein is washed over the solid support and any proportion which binds to the immobilized protein is detected using antibodies essentially as in a western blot. Detection is achieved using horseradish peroxidase (HRP) -linked secondary antibodies in conjunction with ECL (Amersham).
Antibodies. A mouse monoclonal antibody (MAb) against Ad5 hexon was utilized together with a rabbit polyclonal anti-V1 antibody raised against a recombinant polypeptide containing amino acid residues 94-170 of pVI from Ad2 (clone r94-170 described below). The mouse MAb is group specific for native hexons (i.e. homotrimers of hexon polypeptides) and does not react with denatured hexon polypeptides as displayed by western blotting after boiling in denaturing mix. Both antibodies have been more fully described in Matthews & Russell (1994) .
Cells, virus and hexon preparation. These items were as described previously (Matthews & Russell, 1994) .
Construction of deletion clones of pVL PCR amplification, cloning and sequencing of recombinant pVI clones were generally as described before (Matthews & Russell, 1994) . A list of PCR amplification parameters is given in Table 1 and Fig. 1 (a) showing which combinations of primers and restriction enzymes were used to generate the various recombinants. The numbering of recombinants refers to the first and last amino acids from pVI of Ad2 that will be expressed by the recombinant clone. In all cases the product was ligated into similarly restricted pRSETA (Invitrogen) expression vector and transformed into strain XL1 BLUE (Stratagene) of Escherichia colt. This vector places the gene to be expressed downstream of a T7 RNA polymerase promoter and inserts a '6 histidine' nickel-binding motif at the N terminus of the recombinant protein. Some of the constructs (e.g. r36--170) utilized restriction sites already present in the sequence of the pVI gene. Plasmids were all screened for correct orientation and retention of the 5' cloning site by restriction mapping. Additionally, several clones (indicated in Table 1 ) were sequenced to confirm reading frame and authenticity using methods and sequencing primers described previously (Matthews & Russell, 1994) . The following primers were designed: 1 : 5' GGTCCTGTAAGGATCCGGTAGAATGGAAGAC 3' 2: 5' GCACCGGATCCATGAGCGGTGGCGCCTTCAGC 3' 3: 5' CCTTCAGCTGGGGATCCCTTGTGGAGCG 3" 4: 5' TTCGGATCCACCATTAAGAACTATGGCAGC 3' 5:5 r TTGGGATCCCAAAATTTCCAACAAAAGGTGG 3' 6: 5' GGCATCAGCTGGGTGGTGGACGGATCCAACCAGGC 3' A: 5' GGCGGCGACATGGATCCATACATGACACATA 3' B: 5" GCTTCAGGGATCCCACTCACAGACCCACG 3" C: 5' CCCAGGATCCTTTACAGTGTGCTTTGCC 3" D: 5' CAGTGTGCGGATCCATTAGCCACTGGTTACG 3' E: 5' GCTGGCCCGGGAATTCGGTAGCC 3'
In all cases restriction sites engineered into the amplified DNA are underlined once; numbered primers anneal at the 5' end of the PCR product. Primers B, C and D have nucleotides altered to replace codons (double underlined) for amino acids 240, 234 and 228 in the pVI protein with stop codons. Primer 1 alters nucleotide 1 t 8 to change a cysteine codon in the sequence upstream of the pVI gene to a glycine codon (double underlined) preventing the possibility of an anomalous disulphide bond being created between the recombinant proteins. Initially a primer was used (primer 7: 5' GGTCCTGTAAGGATCC-TGTAGAATGGAAGAC 3') in place of primer 1 to generate recombinants rpVI and rl-170. Clone rpVI was remade with primer 1 Akusjarvi & Persson (1981) . "~ Sequencing was performed as described in Matthews & Russell (1994) . and the recombinant protein did not appear to have altered hexon binding properties; this new recombinant was used throughout. No further recombinants were made using primer 7 and it was decided not to modify rl-170 in this way since it seemed highly unlikely that it would have altered hexon binding properties in our assays. It was also decided to investigate the effect of the removal of the vector sequences on hexon binding and a primer was designed, primer 8: 5' GCATTAAACATATGGGTTCCAACC 3', which introduces a methionine codon as part of an NdeI site immediately N-terminal to amino acid 48 in the pVl protein. The amplified product was introduced into NdeI-and BamHI-restricted pRSETA thus removing the vector sequences and utilizing the methionine codon of the PCR product as the initiation codon (rM48-239). For the removal of the five amino acids proximal to the N-terminal cleavage site in pVI, two new primers were made: primer F: 5" GGCGGCGACATAGATCTATACAT-GACACATA 3' and primer G: 5' GCTGAAGGATCCACCGC-TCATATTGC 3'. Primer F is similar to primer A except that it has a BgllI site instead ofa BamHI site and primer G is designed to introduce a BamHI site at the N-terminal cleavage site of pVI. For the internal deletion clone (rpVIdel) primers 3 and F were used to amplify by PCR the sequences between nucleotides 224 and 922. The purified fragment was then cut with BgtII and BamHI and ligated into BamHI-restricted pRSETA. In the correct orientation this protocol retains the BamHI site at the 5' end of the gene but the 3' BglII site is lost. Next, primers 1 and G were utilized to amplify the region between nucleotides 102 and 231; this product was cut with BamHI and ligated into the above BamHI-cleaved construct. In effect this procedure removes five amino acids immediately C-terminal of the N-terminal cleavage site without affecting the consensus sequence required for recognition by the adenovirus protease (see Fig. 1 
b for further clarification of the construct).
Expression and purification of recombinant proteins. The E. eoli strains BL21 (DE3) or the derivative BL21 (DE3) pLysE (Novagen) were utilized for small-scale expression of all the recombinant proteins using the procedures outlined in Matthews & Russell (1994) . Usually 5 ml cultures were established and expression induced once the OD~o o had reached about 0-4, by addition of IPTG to 1 raM. At various times post-induction (normally' 30min) l ml aliquots of culture were removed, the bacteria collected by centrifugation and the samples frozen. Expression and purification of recombinant pVI derivatives from 500 ml cultures was essentially as described by Matthews & Russell (1994) for the production of 'recombinant iVI'. Briefly, at 30 min post-induction the bacteria were harvested and the recombinant protein purified on nickel-agarose beads (kindly supplied by Dr C. Botting, University of St Andrews) in the presence of 6 u-guanidine hydrochloride, 20 mM-2-mercaptoethanol and 20 mM-Tris-HCl (pH 8). After elution from the column with imidazole (250 mM in 20 mMTris-HC1 pH 8"0) the proteins were dialysed against 20 mM-Tri~HC1 Those recombinants which will activate the recombinant 23K protease without the peptide 'CT' being added in trans are indicated. For the binding to hexon, an arbitrary scale based on visual inspection was used with none indicating no binding being detected at all (e.g. r98 250), poor indicating binding broadly similar to that of pVI from infected cells (e.g. rpVI) and good indicating good binding similar to that of iVI from infected cells. (e.g. riVI) On this arbitrary scale the binding of authentic VI from infected cells might be considered to rate excellent. A rating of very poor was given to those clones (e.g. rl 170) whose binding was markedly worse than that of pVI but did still demonstrate some weak binding activity. ND, Not determined.
(pH 8). These procedures were used because all the fusion proteins which contained amino acids between positions 38 and 48 of pVI were highly toxic to E. coli (see Results). Typically the purification of all 'toxic' proteins yielded approximately 3 6 gg of protein at a concentration of 5-10gg/ml whereas the production of 'non-toxic' recombinants yielded about 2 mg of protein at a concentration of approximately 1 mg/ml. Bacterially expressed recombinant adenovirus 23K protease was produced as described by Webster et al. (1993) .
Binding of hexon to Ni-agarose-immobilized recombinant proteins. Samples containing recombinant proteins rpVI and riVI bound to the Ni column support via the 'six histidine motif' were incubated with hexon in PBS for 1 h (approximately 500 ng rpVI/riVI incubated with approximately 100 ~tg hexons, about a 20-fold molar excess of hexons). They were then washed extensively in PBS before removal of the recombinant proteins by addition of 250 mM-imidazole in 20 mMTris-HC1 pH 8. The samples (and several dilutions) were analysed by SDS PAGE and the protein (hexon and recombinant protein) content compared by staining with Coomassie Brilliant Blue.
Examination of proteolytie processing by recombinant 23K protease.
Aliquots of recombinant protein (approximately 5(~100 ng) were incubated with 23K recombinant protease (about 40 ng); BSA (0-5 lag); 10mN EDTA; 20 mi-Tri~HC1 pH 8 and activating peptide (CT; 30 ng) as indicated -all in a final volume of 20 gl. The samples were incubated at 37 °C for various times before analysis by western or westwestern blotting. Controls omitting the protease or CT were also incubated to monitor the possibility of contaminating proteases in the preparations. The activating peptide, CT, is derived from the Cterminal 11 amino acids of pVI (GVQSLKRRRCF) as described in Webster et aL (1993) .
Activation of 23K protease by recombinant proteins derived from p VI.
Activation was assessed by a peptide substrate cleavage assay described previously (Greirson et al., 1994) containing various concentrations of CT or purified recombinant protein together with 90 nN-recombinant 23K protease. The extent of activation of recombinant 23K protease was assessed by determining the percentage cleavage of a known quantity (0.2 mmol) of the substrate peptide LSGAGFSW after various times of incubation at 37 °C.
Determination of the stoichiometry of hexon iVI and hexon-pVI interaction. Samples (1 gl) of purified hexon and Ni-agarose-purified recombinant protein r48-239 were spotted onto nitrocellulose in doubling dilution series. Four identical dot-blots were made and treated as follows: (i) as in a 'west-western' procedure to determine the binding of hexons to r48-239; (ii) as in a 'west-western' procedure to determine the binding of r48-239 to hexons; (iii) as in a western blot to determine the limit of detection of hexons with the mouse anti-hexon MAb and (iv) as in a western blot using anti-VI rabbit antiserum to determine the limit of detection for r48 239. The quantity and purity of protein in each sample was determined by SDS-PAGE, staining the protein band with Coomassie Brilliant Blue and comparing to standard concentrations of BSA on the same gel. As an independent method of assaying protein content, the samples and BSA were spotted onto nitrocellulose and the proteins stained with Naphthalene Black.
Results
To analyse the molecular parameters regulating the binding between hexon and pVI, we attempted to express pV! in a variety of E. coli expression vectors. It soon became evident that expression invariably induced lysis (evidenced by a reduction in the OD600 of the cultures) of the cells and any expressed product appeared to be rapidly degraded by cellular proteases.
Two strategies were adopted to circumvent these shortcomings. Firstly, the gene products were fused to a six-histidine Ni-binding motif. This procedure allowed purification of the recombinant protein under denaturing conditions, thereby reducing its degradation by cellular proteases to acceptable levels. Secondly, transcription of the recombinant genes was placed under the control of a T7 RNA polymerase promoter permitting us to utilize the E. coli strain BL21 (DE3) pLysE (Novagen). This strain allows very tight control of expression compared to BL21 (DE3) (which expresses T7 RNA polymerase) from which it was derived. Sixteen different pVI recombinants were constructed as described in the Methods section and then expressed using the above strategies. Nine of the recombinant proteins were purified using the Ni-agarose columns as outlined in the Methods (Fig. 2) .
Location of sequences associated with toxicity
The toxicity of the recombinant proteins in E. coli was apparent from two properties. Firstly, strain BL21 (DE3) (which may express T7 RNA polymerase at low levels prior to induction) could not be transformed by some recombinant plasmids. Secondly, after inducing expression in the pLysE derivative (as indicated above) culture lysis ensued with an approximately 50% reduction in OD600 after just 30 min (data not shown). These phenotypes were evident only with those constructs which expressed recombinant proteins containing amino acid residues between codons 38 and 48 in the pVI sequence (see Fig. 2 
Vector-derived sequences do not have a significant effect on the binding of hexon protein in the west-western assay
We investigated the possibility that the approximately 43 vector-derived residues in the recombinant proteins might influence the binding of hexon in a west-western assay. Fig. 3 (b) shows hexon binding to recombinants riVI, r48-239, rM48-239 and pVI, iVI and VI from infected cell extracts; a western blot of a duplicate gel is also shown to provide a basis for comparison (Fig. 3 a) . Visual inspection of these results indicates that the binding of rM48-239 and r48-239 was of the same order (i.e. much greater than that of pVI). It is also notable that they seemed to bind hexon more effectively than iVI or riVI, but less effectively than authentic VI from infected cells (see Fig. 2 ). Fig. 4 (a) shows an anti-VI western blot detecting antigen in a range of expressed recombinant proteins in crude bacterial extracts (approximately 2-10 ~g total protein per sample). Fig. 4 (b and c) shows a 'duplicate' west-western blot to demonstrate the range of hexon binding exhibited by the various recombinants. Visual comparison of recombinants rpVI/riVI and r48-250/r48 239 shows that removal of the C-terminal 11 amino acids (riVI) greatly improves hexon binding under these conditions. However, deletion of 17 amino acids from the C terminus (rl-233) dramatically reduces hexon binding -compare recombinants riVI and rl-233. Removal of the C-terminal 80 amino acids (rl-170) reduces binding still further (relative to rpVI and rl-233) but does not completely abolish it.
Binding of hexon protein to recombinant p VI proteins
Visual comparison of recombinants riVI, r48-239 and r74-239 indicates that whereas the N-terminal 48 amino acids can be removed without reducing the binding relative to riVI, removal of the next 26 amino acids (r74-239) markedly reduces the binding to hexon.
A summary of the recombinants made and their relative binding to hexons is shown in Fig. 2 . We have not attempted to quantify the binding abilities of our recombinants for two reasons; firstly, any quantification would be quite crude because of the wide range of binding demonstrated and secondly because of the problems inherent in quantification mainly on the basis of ECL detection.
From these studies, the boundaries of the regions of protein VI apparently critical for hexon binding are between amino acids 48 74 and 234-239 (presented as the C terminus of the polypeptide). Interestingly, each determinant can independently bind hexon, although weakly. For example, clone rl 170 (containing amino acids 48-74) does demonstrate some weak hexon binding. Similarly, weak hexon binding can be detected with r98-239 (amino acids 234-239 presented as the C terminus) but not with r98 250. The recombinant rpVIdel which does contain both regions exhibits similar binding properties to that of rpVI despite the removal of five amino acids just after the N-terminal cleavage site (data not shown; Fig. 2 ). Brilliant Blue. As can be seen in Fig. 5 , hexon bound to both recombinant clones with equal efficacy, indicating that the hexon recognition signals were significantly altered when histidine motifs derived from the vector were bound to the solid support. An experiment (not shown) with r48-239 immobilized on a Ni-agarose column gave similar results. A control experiment (not shown), without recombinant protein, showed that hexon does not bind the Ni-agarose column on its own. 
Stoichiometry of the interaction between r48-239 and hexon
Samples of known quantities of native hexon and r48-239 were spotted onto nitrocellulose, in a dilution series, to assess the limits of detection of the antibodies used to detect the proteins (see Methods). From these assays (data not shown) it was evident that under these conditions hexon antigen could be just detected at 5 ng and r48-239 at 20 ng. When duplicate samples were washed with the standard hexon and r48-239 solutions (about 1 lag/ml), the results indicated that hexon bound to r48-239 could be just detected at 2.5 ng of immobilized r48-239. Correspondingly, the r48-239 bound to hexon could be just detected at 39 ng of native hexon (i.e. 20 ng r48-239 bound to 39 ng of immobilized hexon). Assuming M r for the proteins of 360 kDa for the hexon trimer and 28 kDa for the recombinant r48-239, we calculated the molar ratios of hexon and r48-239 in the two experiments-both ratios were approximately 1:6 (hexon : r48-239).
Binding of hexon to recombinant p VI immobilized on a Ni column via the histidine tag
The hexon binding properties of the recombinant proteins rpVI and riVI, whilst still immobilized on the Ni-agarose column via the 'six histidine motif', were examined. After eluting the bound recombinant rpVI and riVI with imidazole, the samples were boiled prior to analysis by S D S -P A G E and staining with Coomassie
Activation of recombinant 23K protease by recombinant clones of p VI
Since a peptide derived from the C-terminal 11 amino acids of pVI (CT) has been shown to activate the protease it was pertinent to ascertain the comparative activation characteristics of recombinant pVI and iVI. We found that both rpVI and the peptide (30 nM in both cases) activated the recombinant protease with similar efficacy over a time period of 1 h (data not shown). Recombinant iVI did not activate the protease even at higher concentrations (260 riM); this is consistent with the absence of the critical C-terminal 11 residues.
Processing of recombinant pVI and deletion mutants of p VI with recombinant 23K protease
In the purified preparations of rpVI, the full-length product constitutes about one-third of the total protein (by western blotting; Fig. 6a, lane 1) . We believe the other products are derived from rpVI by specific degradation at the C terminus by E. coli proteases (purification requires that the N terminus is intact). That there are more degradation products in the purified protein compared to the crude bacterial extracts (e.g. Fig. 4 ) would seem to indicate that further degradation occurs during the purification procedure. The vectorderived sequences contain amino acid residues (MTGGQQ) which fulfil the consensus requirements for cleavage by the adenovirus protease (Webster et al., 1989) . This sequence is 18 residues upstream of the N terminus and does appear to be recognized by the protease. Recombinant protein r36-170 does not contain a pVI-derived cleavage site but is processed by the recombinant protease in the presence of activating peptide giving rise to a product with an apparent molecular mass consistent with the loss of 18 amino acids from the substrate protein (not shown). Purified rpVI was subjected to proteolysis by the recombinant 23K protease for various times (Fig. 6a) . After processing of rpVI by the adenovirus protease, only two of the products showed any binding of hexons in the westwestern 'duplicate' blots (these being pVIa and VI, see In all cases CT refers to the C-terminal 11 amino acids derived from pVI (see Fig. 7 ). lanes 2 and 3). On the basis of their hexon binding properties and a p p a r e n t molecular masses, we believe these p r o d u c t s can be putatively identified as analogous to iVI and V! from infected cell extracts, respectively (i.e. rpVIa is rpVI cleaved at the C-terminal consensus cleavage site and at the vector-derived site mentioned above). N o t e that rpVI cleaved at b o t h the N-and Cterminal pVI cleavage sites demonstrates the strongest hexon binding. 3) reveals that the i m p r o v e m e n t in binding on processing is retained by the deletion m u t a n t despite it lacking the five amino acids revealed at the N terminus after cleavage. Processing by the protease o f a given a m o u n t o f substrate did not yield c o m p a r a b l e a m o u n t s of the predicted products. Neither riVI (not shown) nor r l -1 7 0 (Fig. 6 c) a p p e a r to undergo any processing in the presence of r e c o m b i n a n t 23K protease alone. However, with both protease and CT, the substrate is processed but does not yield c o m p a r a b l e a m o u n t s o f r 1-170b (compare lanes 1, 2 and 4 o f Fig. 6 c) . In lanes 2 and 3 the p r o d u c t designated r l -1 7 0 a is believed to be r l -1 7 0 cleaved only at the consensus sequence present in the vector-derived sequences; r l -1 7 0 b is r l -1 7 0 cleaved at the N -t e r m i n a l cleavage site from pVI. W e also found that processing o f r l -1 7 0 to r l -1 7 0 b did not improve the ability o f this r e c o m b i n a n t protein to bind hexon (data not shown). Clearly, the c o n f o r m a t i o n of the processed protein, in a d d i t i o n to proteolytic cleavage at the N terminus, is a factor in determining the hexon binding properties of protein VI.
Discussion
In this p a p e r we have shown that two regions o f protein VI are critical for the interaction with hexon. F u rthermore, we investigated the role of the protease in the processing of pVI to VI and found that no other factors are required in vitro. Thus extended our previous investigation into the nature of the hexon-VI interaction (Matthews & Russell, 1994) . Deletion mutagenesis showed that the intermediate, iVI, detected in adenovirus-infected cells, has properties consistent with it being pVI minus the C-terminal 11 amino acids. Thus, recombinant iVI demonstrates similar hexon binding to that of iVI derived from infected cells. Removal of a further six amino acids from the C terminus reduces hexon binding to levels similar to those achieved with rpVI. Comparison of known mammalian adenovirus pVI sequences (human Ads 2, 5, 12, 31, 40, 41 and mouse adenovirus type 1 from the GenEMBL databases) indicates that the C-terminal 12 amino acids of iVI are highly conserved amongst mastadenoviruses (See Fig. 7) . Moreover, in all cases the C terminus of uncleaved pVI is hydrophilic whereas the C terminus of iVI is hydrophobic, suggesting that it may function to bind hexon via a hydrophobic clamp mechanism (perhaps similar to that suggested for VP1 of simian virus 40 by Liddington et al., 1991) . We have previously noted that the interaction between hexon and mature protein VI is sensitive to low levels of non-ionic detergents (Matthews & Russell, 1994) .
The second region, critical for the binding of hexon, is located at least 15 amino acids from the N-terminal cleavage site. Those amino acids apparently critical for the interaction between hexon and iVI are between positions 48 and 74. Again, this region is highly conserved amongst the mammalian adenoviruses (see Fig. 7 ). Both these conclusions are consistent with our previous work showing that determinants of the interaction between hexon and protein VI are group specific in nature (Matthews & Russell, 1994) . Because recombinants r48-250 and rl-170 bind weakly to hexon and r98-250 does not bind at all, we propose that amino acid residues 48-74 are the main determinants of the lowlevel hexon-pVI interaction. However, r36-170 does not bind hexon suggesting that the surrounding conformation is also important (Fig. 2) . We noted that removal of the N-terminal 48 amino acids of iVI appeared to improve hexon binding relative to riVI and iVI from infected cells (Fig. 4) . This would suggest that removal of the N-terminal 33 amino acids of iVI affects the conformation of the protein, improving hexon binding. We also propose that, unlike the C terminus, the Nterminal amino acids of mature protein VI do not play a major role in hexon binding. This contention is supported by the finding that deletion of the five amino acids revealed after cleavage at the N terminus of iVI does not noticeably affect hexon binding (Fig. 6 b) .
Thus for the interaction between hexon and VI, we have found that there are two major determinants: one is the presentation of the C terminus of iVI and the other is the region amino acids 48-74. Either region seems to be sufficient to bind hexon weakly but together they act synergistically. We believe this suggests that both regions may interact directly with the hexon protein and/or that cleavage generates conformational changes facilitating hexon binding. In addition, mixtures of recombinants r98-239 and rl-170 do not associate to form a strong hexon binding site (data not shown) implying, not surprisingly, that the surrounding structures are important and that the two regions must be presented in cis.
We found that rpVI bound to the Ni-agarose support binds hexon as well as fiVI, not in keeping with the results of the west-western blotting assays. We believe the vector sequences anchored to Ni--agarose alter the conformation of rpVI, presenting critical sequences and allowing hexon to bind more effectively. The interaction between hexon and rpVI bound to the column may still be a relatively weak interaction compared to the fiVI-hexon interaction. It was not possible to determine if riVI could effectively compete for the hexon bound to immobilized rpVI since the soluble riVI would also bind to the Ni-agarose column. We previously noted that addition of 0"05% Triton X-100 to the west-western assay markedly improves hexon binding to pVI (Matthews & Russell, 1994) -this is perhaps another indication that conformation, as well as sequence content, is important in the recognition process. By contrast, soluble rpVI (released from the Ni-agarose support) binds hexon at very low levels (data not shown) whereas soluble riVI binds to immobilized hexon as shown previously (Matthews & Russell, 1994) . Since the interaction between hexon and protein VI is group specific, this technique could provide an efficient method of extracting hexons, of a variety of serotypes, from infected cell extracts.
Our relatively crude attempts to measure the stoichiometry of the r48-239 -hexon interaction provided results which were remarkably similar to the proposed stoichiometry (i.e. six copies of VI per peripentonal hexon; Stewart et al., 1993) . We believe this demonstrates the high avidity of r48-239 (and so presumably iVI and VI) for hexon. Casual inspection of Fig. 5 indicates a similar stoichiometric relationship between hexon and rpVI/riVI bound to a Ni-agarose column.
We found that recombinant adenovirus protease will mature rpVI to iVI and VI in vitro. Furthermore, these products demonstrated similar hexon binding properties to their in vivo-derived counterparts. Given the definition of our in vitro processing assay, this implies that there are no other factors or processing events involved in the production of mature VI. This is in contrast to the suggestion that DNA may be a co-factor in the activation of the viral protease (Mangel et al., 1993) . Activation of recombinant 23K protease is mediated by an oligopeptide derived from the C-terminal 11 amino acids of pVI (CT; Mangel et al., 1993; Webster et al., 1993) . We have shown that CT activates recombinant 23K protease apparently as efficiently as rpVI. Moreover, only constructs containing the C-terminal 11 amino acids will perform this role, which is vital to the production of mature infectious virus in vivo. Whilst perhaps not surprising, it is noteworthy that the main body of rpVI does not apparently play any part in the activation of recombinant 23K protease in our assays. Greber et al. (1993) proposed that the protease is responsible for the degradation of VI shortly after entry into a host cell. In our own assays we noted that a given amount of substrate incubated with protease and CT (supplied in trans or in cis with respect to the substrate) did not yield comparable amounts of the predicted product, suggesting further degradation may have occurred. This phenomenon was dependent on the presence of CT in the assay, implying that adenovirus protease may have been involved.
We envisage that during infection, the protease might become closely associated with pVI in the 'young virion' (Ishibashi & Maizel, 1974) . In the appropriate environment, protease would then recognize and, following activation, cleave the C terminus of pVI to produce iVI -the cascade of proteolysis would then be initiated. Cleavages at both termini could lead to considerable conformational changes in pVI which would, in turn, facilitate hexon binding, acting as a temporal control over hexon-VI interaction. Access of the protease to the other substrates could also be mediated through pVIearlier evidence by Mizra & Weber (1982) had indicated an association of pVI, but not VI, with the core proteins. In view of this, one could speculate that association between pVI and core proteins might be mediated via the N-terminal 33 amino acids cleaved from iVI. Given that there are always reservations about coming to conclusions on the basis of in vitro systems (the protein may be in a multimeric form in vivo), we believe that the 'west-western' assay does throw some light on these early maturation events. In particular, there is no evidence of any post-translational modification of pVI, which might not be reflected when utilizing a prokaryotic-based expression system. We believe our studies show that the adenovirus system is a good model for studying proteolytic processing as a control of maturation and assembly in complex macromolecular structures.
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